Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

South Carolina Attorney General Alan Wilson led a 37-state coalition that wants the FDA to take action against manufacturers ...

Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Ascletis Pharma's oral GLP-1 drug ASC30 shows 6.2% placebo-adjusted weight loss in Phase 1b obesity trial, matching Roche's ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.